Citalopram Mechanism of Action: How It Works in the Brain

Citalopram works primarily by physically blocking the serotonin transporter, a protein on the surface of nerve cells responsible for vacuuming serotonin back out of the gaps between neurons. By plugging this transporter, citalopram leaves more serotonin lingering in those gaps, amplifying the signal between neurons that rely on it. That much is the textbook explanation, and it is accurate as far as it goes, but the full picture involves a second, less well-known binding site on the same transporter, ripple effects across other brain chemicals, changes in how genes are read, and shifts in how entire brain networks communicate.

Physically Blocking the Serotonin Transporter

The serotonin transporter, often abbreviated SERT, is the molecule that pulls serotonin molecules back into the neuron that released them. Citalopram wedges itself into the central binding pocket of SERT, the same pocket where serotonin would normally dock. X-ray crystallography of the human serotonin transporter has shown that when citalopram (specifically the S-enantiomer) occupies this site, it locks the transporter in an outward-facing shape, preventing serotonin from being drawn back inside the cell.¹ The transporter essentially gets stuck mid-cycle, like a revolving door jammed in one position.

What makes citalopram unusual among antidepressants is that the serotonin transporter has a second, less obvious pocket called the allosteric site, located in the extracellular vestibule of the protein. Crystal structures reveal that a second molecule of S-citalopram can occupy this vestibule site at the same time that one molecule sits in the primary pocket. The two binding events are not independent. When a molecule occupies the primary site, it reshapes the protein enough to change how tightly a second molecule binds at the allosteric site, and vice versa.² Mutagenesis work has identified specific amino acids, including Met180, Tyr495, and Ser513, that mediate this coupling between the two sites.³ The practical effect is that citalopram does not just block the transporter once; the allosteric binding may slow its own dissociation from the primary site, prolonging the blockade.

The Two Halves of Citalopram

Citalopram as sold in most generic tablets is a racemic mixture, meaning it contains equal parts of two mirror-image molecules: S-citalopram and R-citalopram. These two enantiomers do not behave the same way at the serotonin transporter. S-citalopram is the therapeutically active half, binding the primary pocket with high affinity and providing the serotonin reuptake inhibition the drug is prescribed for. R-citalopram, by contrast, is a much weaker inhibitor at the primary site but has meaningful affinity for the allosteric site. Research has shown that R-citalopram can actually interfere with S-citalopram’s binding, an antagonistic relationship that was not initially expected when citalopram was developed.⁴

This discovery is the reason escitalopram (Lexapro) exists. By removing R-citalopram entirely and marketing only the S-enantiomer, the idea was to deliver a cleaner, more potent blockade of the serotonin transporter. Binding studies confirm escitalopram is roughly 30 times more potent at SERT than R-citalopram.⁵ Whether that translates into a clinically meaningful advantage for most patients has been debated for years, but the pharmacology is clear: the two mirror-image halves of citalopram pull in different directions at the transporter.

How Citalopram Crosses Into the Brain

A drug that blocks a brain transporter is useless if it cannot get into the brain. The blood-brain barrier is a tightly sealed layer of cells lining brain blood vessels, and most molecules in the bloodstream cannot pass through it. Citalopram enters the brain through a carrier-mediated transport process that shuttles it across endothelial cells in both directions. Importantly, this transport is not stereoselective, meaning both enantiomers cross equally well, and it is not blocked by P-glycoprotein, a molecular pump that actively kicks many drugs back out of the brain.⁶

This is a practical distinction worth knowing. Escitalopram, by contrast, does appear to be affected by P-glycoprotein efflux. Studies in mice found that knocking out P-glycoprotein roughly tripled escitalopram’s brain-to-plasma ratio, meaning the pump normally limits how much escitalopram accumulates in the brain.⁷ Citalopram, with its apparent indifference to the P-glycoprotein pump, may reach brain tissue with fewer barriers. Individual variation in P-glycoprotein activity, which is partly genetic, could matter more for escitalopram users than for people taking racemic citalopram.

Why the Therapeutic Effect Takes Weeks

Citalopram begins blocking SERT within hours of the first dose, and serotonin levels in the synaptic cleft rise quickly. Yet most people do not feel a meaningful improvement in depression for two to four weeks or longer. This disconnect between the fast pharmacological event and the slow clinical benefit has puzzled researchers for decades, and the full explanation is still not settled.

One long-standing hypothesis involved the desensitization of serotonin autoreceptors. Serotonin-producing neurons have receptors on their own cell bodies (called 5-HT1A autoreceptors) that act as a volume knob. When serotonin floods the synapse, these autoreceptors detect the increase and tell the neuron to slow down its firing. The theory was that over weeks, these autoreceptors gradually lose their sensitivity, allowing the neuron to fire at a normal rate despite the elevated serotonin, thereby restoring more balanced signaling.

However, research in rats using chronic citalopram found that the therapeutic delay did not appear to be linked to a downregulation of 5-HT1A receptor density or to the uncoupling of these receptors from their signaling partners. Instead, the study pointed to increased functional sensitivity of postsynaptic 5-HT1A receptors, the ones on the receiving neurons, in brain regions like the frontal cortex and hippocampus.⁸ In other words, the weeks-long delay may have more to do with the receiving end of the serotonin signal becoming more responsive than with the sending end calming down. The full mechanism is probably a combination of factors, but the simple “autoreceptor desensitization” story does not capture the whole picture.

Ripple Effects on Dopamine and Norepinephrine

Citalopram is classified as a selective serotonin reuptake inhibitor, but “selective” does not mean serotonin is the only neurotransmitter affected. Serotonin neurons project into brain regions that also rely on dopamine and norepinephrine, so altering serotonin tone inevitably has downstream consequences.

In rats treated with citalopram for 14 days, baseline norepinephrine levels in the prefrontal cortex dropped to about 40% of normal. Meanwhile, baseline dopamine levels were unchanged, but the dopamine response to a mild stressor was blunted: control animals showed a surge in prefrontal dopamine when stressed, while citalopram-treated animals did not.⁹ These changes were tied to prefrontal cortex 5-HT1A receptors, further reinforcing how much citalopram’s serotonin-focused action reverberates through other systems.

This cross-talk helps explain some clinical observations. The emotional blunting that some people report on SSRIs, a feeling of muted highs and lows, could relate to this dampened dopamine stress response. Similarly, the fact that citalopram lowers norepinephrine in the prefrontal cortex hints at why some patients whose depression involves fatigue or low motivation may not respond as well to a pure serotonin-focused drug.

Changing How Brain Regions Talk to Each Other

Beyond individual neurotransmitter levels, citalopram appears to alter the communication patterns between entire brain regions. In a placebo-controlled brain-imaging study, acute citalopram infusion strengthened the functional connectivity between the medial prefrontal cortex and both the dorsolateral prefrontal cortex and the posterior cingulate cortex. At the same time, the variability of that connectivity dropped, meaning these regions communicated more consistently under citalopram than under placebo.¹⁰

The medial prefrontal cortex is heavily involved in self-referential thinking and emotion regulation, while the posterior cingulate is a hub of the brain’s default mode network, active during rumination and internal thought. In depression, this default mode network is often overactive and loosely regulated. Tighter, more stable communication between these regions could be part of how citalopram helps break the cycle of rumination, though this was an acute dosing study, and longer-term connectivity changes may differ.

Resetting the Stress Hormone System

Depression is frequently accompanied by an overactive stress hormone system. The hypothalamic-pituitary-adrenal (HPA) axis, which governs cortisol release, tends to run on overdrive in people with depression, with the normal feedback loop that shuts off cortisol production after a stressor becoming less effective.

Citalopram appears to restore this feedback loop quickly. In healthy volunteers, just four days of citalopram treatment was enough to increase the ability of a synthetic steroid to suppress cortisol release, a sign that the glucocorticoid receptors responsible for shutting down the HPA axis were functioning more effectively.¹¹ This is faster than the typical onset of mood improvement, which raises the possibility that normalizing the stress hormone system is an early step in citalopram’s therapeutic cascade, potentially setting the stage for later mood changes rather than directly causing them.

Effects on Brain Immune Cells

Microglia, the brain’s resident immune cells, are increasingly recognized as players in depression. When activated by inflammation, microglia release signaling molecules that can impair neuronal function. Citalopram has been shown to affect microglial activity, though the evidence is not fully consistent. In rat primary microglia, citalopram prevented the inflammatory production of several key signaling molecules, including IL-1β, TNF-α, and nitric oxide, when the cells were challenged with an inflammatory stimulus. However, in a mouse microglial cell line, only high concentrations of citalopram reduced TNF-α, and nitric oxide production was unaffected.¹²

The discrepancy likely reflects differences between cell types, species, and the artificial conditions of lab experiments. Still, the general direction of the evidence suggests citalopram has some anti-inflammatory effect in the brain, which could contribute to its therapeutic benefit independently of serotonin reuptake inhibition, particularly in patients whose depression has a strong inflammatory component.

Epigenetic Fingerprints

One of the more surprising discoveries about citalopram is that it changes how genes are chemically tagged for reading. A genome-wide analysis of DNA methylation in human cells exposed to citalopram found significant changes in the methylation patterns of over 600 gene promoters. More were hypermethylated (turned down) than hypomethylated (turned up). Among the affected genes were several previously linked to depression, including genes involved in brain signaling, hormone metabolism, and a gene encoding oxytocin. The study also found altered methylation of several epigenetic enzymes themselves, including SIRT1 and HDAC6, which regulate how tightly DNA is packaged.¹³

These epigenetic changes offer a possible mechanism for some of citalopram’s longer-term effects. If the drug alters which genes are being actively read, that could contribute to the gradual remodeling of neuronal circuits that underlies sustained mood improvement. It also raises questions about whether some of these gene-expression changes persist after the drug is stopped.

How the Body Breaks Down Citalopram

Citalopram is metabolized in the liver primarily through a process called N-demethylation, carried out by three enzymes from the cytochrome P450 family: CYP3A4, CYP2C19, and CYP2D6.¹⁴ This matters for two reasons. First, people carry different genetic variants of these enzymes, particularly CYP2C19. Someone who is a “poor metabolizer” at CYP2C19 will clear citalopram more slowly, leading to higher blood levels at the same dose. Genetic testing for CYP2C19 status is increasingly available and is used by some clinicians to guide dosing. Second, other medications that inhibit these enzymes can raise citalopram levels unexpectedly. Common culprits include certain antifungal drugs (CYP3A4 inhibitors) and proton pump inhibitors like omeprazole (CYP2C19 inhibitors).

The Cardiac Side of the Story

Citalopram has an effect on the heart that is unrelated to serotonin. It can block hERG potassium channels in heart muscle cells, channels responsible for one phase of the electrical cycle that keeps heartbeats regular. Blocking these channels delays the repolarization of heart cells, which shows up on an electrocardiogram as a prolonged QTc interval.¹⁵ A prolonged QTc can increase the risk of a dangerous heart rhythm called torsades de pointes, though the absolute risk at normal doses is very low in otherwise healthy people.

This cardiac effect led the FDA in 2011 to cap the recommended maximum dose of citalopram at 40 mg per day for most adults and 20 mg per day for people over 60. The dose ceiling is specifically about this potassium channel effect, not about serotonin. For most patients, the QTc prolongation at therapeutic doses is small, but it becomes clinically relevant in people who already have heart rhythm problems, who are taking other QTc-prolonging medications, or who have electrolyte imbalances such as low potassium or magnesium.

What Happens When You Stop

Discontinuation symptoms, sometimes called SSRI discontinuation syndrome, can include dizziness, irritability, electric-shock sensations, and mood changes. The mechanism behind these symptoms is not as thoroughly studied as the mechanism of the drug’s therapeutic action. Evidence points to a rebound increase in the excitability of serotonin neurons immediately after SSRI treatment stops, essentially the opposite of what the drug was doing while being taken. Researchers have drawn parallels to withdrawal states seen with other drugs that act on the central nervous system, though the intensity of SSRI discontinuation is generally milder.¹⁶

Citalopram has a half-life of roughly 35 hours, meaning it clears the body over several days. This is a middle-of-the-road elimination speed among SSRIs. Fluoxetine, by comparison, has an active metabolite that lingers for weeks, effectively tapering itself. Citalopram clears faster than that, which is why gradual dose reduction is typically recommended when stopping. The abruptness of the serotonin transporter going from blocked to unblocked is likely what drives the rebound in neuronal excitability, and a slower taper gives the brain more time to readjust.

Effects Citalopram Largely Does Not Have

Given how widely citalopram is prescribed, it is worth noting a few mechanisms it does not meaningfully engage. Unlike some other psychotropic drugs, citalopram has only a weak effect on glutamate receptors. Experiments testing citalopram against NMDA receptors, a major class of excitatory receptors in the brain, found it had minimal inhibitory activity compared to drugs like desipramine or chlorpromazine.¹⁷ This matters because the glutamate system is a major area of interest in newer antidepressant research, particularly with ketamine-derived treatments. Citalopram’s therapeutic action operates through a fundamentally different pathway.

Citalopram also has negligible affinity for histamine, muscarinic, and adrenergic receptors at therapeutic doses, which is why it tends to cause fewer side effects like sedation, dry mouth, and blood pressure changes than older tricyclic antidepressants. Its selectivity for the serotonin transporter is both its main therapeutic advantage and its main limitation: it does one thing well but leaves other neurotransmitter systems to be influenced only indirectly, through the serotonin-mediated cross-talk described earlier.